Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Omniscient announced its third FDA clearance, for deep brain stimulation lead targeting, on September 11.</li><li>Scheeler described the new DBS tool as device-agnostic and was built after a major DBS player asked to use Omniscient’s connectome mapping to guide placement of its implant.</li><li>A full release is planned in the month ahead. Scheeler framed the clearance as the first step beyond tumor resection into neurology and movement disorders such as Parkinson’s and as another reason for a hospital to order a scan and keep the platform.</li></ul>

Omniscient announced its third FDA clearance, for deep brain stimulation lead targeting, on September 11.Scheeler described the new DBS tool as device-agnostic and was built after a major DBS player asked to use Omniscient’s connectome mapping to guide placement of its implant.A full release is planned in the month ahead. Scheeler framed the clearance as the first step beyond tumor resection into neurology and movement disorders such as Parkinson’s and as another reason for a hospital to order a scan and keep the platform.

From Guesswork to Brain Maps: A New Foundation for Mental Health

<div><ul><li>Omniscient secured its third FDA clearance. On September 11, Omniscient announced 510(k) clearance for its Quicktome Deep Brain (DB) workflow, extending its connectomic platform into deep brain stimulation.</li><li>As discussed in our August report, Omniscient had identified DBS as the next platform extension, with a submission already filed and clearance expected by the end of 2026.</li><li>The clearance arrived with a full quarter to spare.</li></ul></div>

Omniscient secured its third FDA clearance. On September 11, Omniscient announced 510(k) clearance for its Quicktome Deep Brain (DB) workflow, extending its connectomic platform into deep brain stimulation.As discussed in our August report, Omniscient had identified DBS as the next platform extension, with a submission already filed and clearance expected by the end of 2026.The clearance arrived with a full quarter to spare.

<ul><li>Making brain data actionable at scale. Founded in 2019 by neurosurgeon Dr. Michael Sughrue and data scientist Dr. Stephane Doyen and led by the former CEO of Facebook Australia and New Zealand, Omniscient commercializes connectomic analysis and visualization, turning scans from MRI machines hospitals already own into patient-specific views of brain wiring and network activity. </li><li>Quicktome received its first FDA clearance in 2021 for turning diffusion MRI into maps of the brain’s white-matter wiring and in 2023 became the first FDA-cleared platform to generate motor, language, and vision correlation maps from resting-state functional (fMRI); it has been used in ~20,000 processed cases at ~100 US hospitals and clinics.</li><li>Neurosurgery alone could become a multi-hundred-million-dollar business. </li></ul>

Making brain data actionable at scale. Founded in 2019 by neurosurgeon Dr. Michael Sughrue and data scientist Dr. Stephane Doyen and led by the former CEO of Facebook Australia and New Zealand, Omniscient commercializes connectomic analysis and visualization, turning scans from MRI machines hospitals already own into patient-specific views of brain wiring and network activity. Quicktome received its first FDA clearance in 2021 for turning diffusion MRI into maps of the brain’s white-matter wiring and in 2023 became the first FDA-cleared platform to generate motor, language, and vision correlation maps from resting-state functional (fMRI); it has been used in ~20,000 processed cases at ~100 US hospitals and clinics.Neurosurgery alone could become a multi-hundred-million-dollar business. 

Omniscient Neurotechnology Pty Limited: Making Brain Data Actionable at Scale

Australia

Omniscience Corporation develops a cloud-based connectomic analysis platform for the healthcare and research sectors. The company utilizes artificial intelligence and federated learning to transform MRI scans into detailed maps of brain networks, identifying neurological connections for neurosurgery, neurology, and neuroscience applications. Omniscience serves academic researchers and healthcare professionals worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Omniscient (OMNISCIENT AU)

From Guesswork to Brain Maps: A New Foundation for Mental Health

Scheeler described the new DBS tool as device-agnostic and was built after a major DBS player asked to use Omniscient’s connectome mapping to guide...

Water Tower Research

Omniscient Neurotechnology Pty Limited

Omniscient secured its third FDA clearance. On September 11, Omniscient announced 510(k) clearance for its Quicktome Deep Brain (DB) workflow...

Water Tower Research

Omniscient Neurotechnology Pty Limited: Making Brain Data Actionable at Scale

Founded in 2019 by neurosurgeon Dr. Michael Sughrue and data scientist Dr. Stephane Doyen and led by the former CEO of Facebook Australia and New...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)